Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SLC11A2 | P49281 | 11/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571006 | 0.81 | SLC11A2 (0.52) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL2565341 | 0.78 | GAA (0.52) | GABRA1GABRG2GABRB3GABRA3SLC11A2 | |
| SCHEMBL11269804 | 0.76 | MEN1 (0.93) | MEN1KMT2AGAAMAPK1KDM4E | |
| SCHEMBL3532027 | 0.73 | MEN1 (1.00) | MEN1KMT2AGAAMAPK1KDM4E | |
| SCHEMBL3535509 | 0.72 | MEN1 (0.97) | MEN1KMT2AGAAMAPK1KDM4E | |
| SCHEMBL6910957 | 0.71 | SLC11A2 (0.48) | MEN1KMT2ASLC11A2KDM4EALDH1A1 | |
| SCHEMBL2569636 | 0.70 | GAA (0.47) | GABRA1GABRG2GABRB3GABRA3SLC11A2 | |
| SCHEMBL11411739 | 0.70 | GAA (1.00) | GABRA1GABRG2GABRB3GABRA3SLC11A2 | |
| SCHEMBL11591539 | 0.68 | MEN1 (0.67) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL30493292 | 0.67 | SMN1; SMN2 (0.56) | GABRA1GABRG2GABRB3GABRA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | claimed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | claimed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | claimed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | claimed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | disclosed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | disclosed |
| US-8697731-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | disclosed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | GABRA1 248/4885GABRG2 355/4885GABRB3 175/4885 |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | GABRA1 248/4885GABRG2 355/4885GABRB3 175/4885 |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | GABRA1 248/4885GABRG2 355/4885GABRB3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.